TUSSICAPS 5mg/4mg CII
Generic Name and Formulations:
Hydrocodone bitartrate 5mg, chlorpheniramine maleate 4mg; as polistirex; ext-rel caps; contains alcohol.
Indications for TUSSICAPS 5mg/4mg:
Cough and upper respiratory symptoms.
1 cap (10mg/8mg) every 12hrs; max 2caps/24hrs.
<6yrs: see Contraindications. 6–11yrs: 1 cap (5mg/4mg) every 12hrs; max 2caps/24hrs.
Children <6yrs of age (risk of fatal respiratory depression).
Respiratory depression. Post–op. Pulmonary disease. Head injury. Increased intracranial pressure. Glaucoma. Asthma. GI or GU obstruction. Acute abdomen. Severe hepatic or renal impairment. Hypothyroidism. Addison's disease. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Antitussive + antihistamine.
Additive CNS depression with alcohol, other CNS depressants, tricyclic antidepressants, MAOIs. Paralytic ileus with concurrent anticholinergics.
Nausea, vomiting, CNS and respiratory depression, ureteral and vesical sphincter spasm, chest tightness, abuse potential, anticholinergic effects, rash, pruritis.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC